Pathologic complete response of ductal carcinoma in situ to neoadjuvant systemic therapy in HER2-positive invasive breast cancer patients: a nationwide analysis

Autor: Roxanne Ploumen, Eva Claassens, Loes Kooreman, Kristien Keymeulen, Maartje van Kats, Suzanne Gommers, Sabine Siesling, Thiemo van Nijnatten, Marjolein Smidt

Purpose Ductal carcinoma in situ (DCIS) is present in more than half of HER2-positive invasive breast cancer (IBC). Recent studies show that DCIS accompanying HER2-positive IBC can be completely eradicated by neoadjuvant systemic therapy (NST). Our a

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::3af94bffdb33cbf26de4e5da983e982a
https://doi.org/10.21203/rs.3.rs-2731537/v1

Longitudinal serum protein analysis of women with a high risk of developing breast cancer reveals large interpatient versus small intrapatient variations

Autor: Sophie Hagenaars, Lennard Dekker, Bob Ravesteijn, Ronald van Vlierberghe, Fred Romijn, Linda Verhoeff, Arjen Witkamp, Karin Schenk, Kristien Keymeulen, Marian Menke-Pluijmers, Anneriet Dassen, Birgitta Kortmann, Jakob de Vries, Emiel Rutgers, Yuri van der Burgt, Elma Meershoek-Klein Kranenbarg, Christa Cobbaert, Theo Luider, Wilma Mesker, Rob Tollenaar

Publikováno v: International Journal of Molecular Sciences, 23(20):12399. Multidisciplinary Digital Publishing Institute (MDPI)
International Journal of Molecular Sciences; Volume 23; Issue 20; Pages: 12399
International Journal of Molecular Sciences, 23(20):12399. MDPI AG
International Journal of Molecular Sciences, 23(20). MDPI

The prospective, multicenter TESTBREAST study was initiated with the aim of identifying a novel panel of blood-based protein biomarkers to enable early breast cancer detection for moderate-to-high-risk women. Serum samples were collected every (half)

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e19e83269c8b7827518dcb0ddd6cb947
https://hdl.handle.net/1887/3564252

Correlation Between Pathologic Complete Response in the Breast and Absence of Axillary Lymph Node Metastases After Neoadjuvant Systemic Therapy

Autor: Linda de Munck, Thiemo J. A. van Nijnatten, Kristien Keymeulen, Marc B. I. Lobbes, J. M. Simons, Loes F. S. Kooreman, Sabine Siesling, Marjolein L. Smidt, Sanaz Samiei

Publikováno v: Annals of Surgery, 271(3), 574-580. LIPPINCOTT WILLIAMS & WILKINS
Annals of Surgery, 271(3), 574-580. Lippincott Williams & Wilkins
Annals of Surgery, 271, 574-580. Lippincott Williams & Wilkins

Objective: The aim was to investigate whether pathologic complete response (pCR) in the breast is correlated with absence of axillary lymph node metastases at final pathology (ypN0) in patients treated with neoadjuvant systemic therapy (NST) for diff

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b8d66492170d7afb2aea3f9b24c83bfd
https://cris.maastrichtuniversity.nl/en/publications/b4152e18-3560-4a4b-859c-f6ca1fe7caaf

Diagnosed with a Rare Cancer

Autor: Olga Husson, Jos A. van der Hage, Jacco J de Haan, Vicky L. M. N. Soomers, Dirk J. Grünhagen, Cas Drabbe, Winan J. van Houdt, Winette T. A. van der Graaf, Pètra M. Braam, Kristien Keymeulen

Publikováno v: Cancers, 13(4):679, 1-16. Multidisciplinary Digital Publishing Institute (MDPI)
Cancers, 13
Cancers, 13(4), 679. MDPI} {AG
Cancers, 13(4):679. Multidisciplinary Digital Publishing Institute (MDPI)
Cancers
Volume 13
Issue 4
Cancers, 13(4):679. MDPI AG
Cancers, 13(4). MDPI
Cancers, Vol 13, Iss 679, p 679 (2021)
Cancers, 13, 4

The aim of this study was to explore the experience of rare cancer patients with the healthcare system and examine differences between age groups (adolescents and young adults (AYA, 18–39 years), older adults (OA, 40–69 years) and elderly (≥70

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1d7174c89deeb00fb8db3edec41eec4f
https://hdl.handle.net/11370/375ecdd6-7ed6-4a9e-984c-8c42dd5a7feb

Avelumab for advanced Merkel cell carcinoma in the Netherlands

Autor: Mathilde Jalving, Ferry A.L.M. Eskens, Margot E T Tesselaar, Maureen J.B. Aarts, Sonja Levy, Kristien Keymeulen, Lukas B. Been, Alexander C.J. van Akkooi, Dirk J. Grünhagen

Publikováno v: Journal for ImmunoTherapy of Cancer, 8(2):001076. BioMed Central Ltd
Journal for ImmunoTherapy of Cancer, 8(2). BioMed Central Ltd.
Journal for Immunotherapy of Cancer
Journal for immunotherapy of cancer, 8(2):e001076. BMC
Journal for ImmunoTherapy of Cancer, Vol 8, Iss 2 (2020)

BackgroundMerkel cell carcinoma (MCC) is associated with high recurrence rates and poor survival when metastatic disease is present. The immune checkpoint inhibitor avelumab has shown high response rates (RRs) and durable responses in patients with a

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8b23e65afd7480a75ed101dcc1ed25ef
https://doi.org/10.1136/jitc-2020-001076